U.S., Feb. 15 -- ClinicalTrials.gov registry received information related to the study (NCT06828328) titled 'A Study of Gene-edited GC203 TIL on the Pancreatic Ductal Adenocarcinoma' on Feb. 10.
Brief Summary: This study is to investigate the safety and efficacy of gene-edited tumor infiltrating lymphocyte (GC203 TIL) therapy in patients with pancreatic ductal adenocarcinoma. Gene-edited TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
Study Start Date: Feb. 10
Study Type: INTERVENTIONAL
Condition:
Pancreatic Cancer
Pancratic Ductal Adenocarcinoma
Treatment Side Effects
Tumor Infiltrating Lymphocytes...